Two main forms of IGFs have been isolated from human plasma and these two IGFs are structually similar (Rinderknecht and Humbel, 1976, 1978) . Because of the presence of these two IGFs, efforts have been made to develop methods which specifically measure these peptides. Radioimmunoassay for IGF-II is now available in several laboratories (Moses et al., 1980; Zapf et al., 1981; Daughaday et al., 1981; Hintz et al., 1982; Enberg et al., 1984 Monoclonal antibody to rat IGF-II was provided by Amano Pharmaceutical Co. (Nagoya, Japan) (Tanaka et al., 1985 extracted plasma was observed. IGF-I crossreacted with it at a potency 100 times less than IGF-II. The intra-and inter-assay coefficients of variation of the assay were 6.3% and 9.3%. The dilution curve for the acid-ethanol extract of human plasma were parallel to that for the IGF-II standard (Fig. 1) Gel filtration pattern of normal plasma The Sephacryl S-200 gel filtration patterns of IGF-I and IGF-II were observed (Fig. 6 ). There were two peaks of both IGFs, approximately 150K and 40K. The 40K peak of IGF-II was higher than that of IGF-I.
Discussion
In the present study we reported IGF-II concentrations in man in physiological and pathological conditions determined by a specific and sensitive radioimmunoassay with biosynthetic IGF-II.
This antibody to IGF-II was specific for IGF-II and cross reactivity with IGF-I was 1%. Zapf et al.(1981) and Enberg et al.(1984) reported that their polyclonal antibody to human IGF-II exhibited 10% cross-reactivity with IGF-I and their RIAs required correction for IGF-I content. Our RIA did not require it. Fifty percent displacement of 125I-IGF-II in our RIA was 50 pg/tube (100pg/ml) while it was 1-2ng/ml in other RIAs. Therefore, we could detect even a very small amount of IGF-II in various samples with this assay.
Plasma IGF-II in patients with active acromegaly was increased, and then decreased after operation. Plasma IGF-II in hypopituitarism was low. When these patients were treated with hGH, IGF-II increased slightly, but not significantly. Our data suggest that IGF-II might be partially GH dependent, but this GH dependency is less than that of IGF-I. It has been reported that no increase in IGF-II was found in patients with acromegaly, whereas GH deficiency was accompanied by significantly lower concentrations (Zapf et al. 1981 , Enberg et al., 1984 . Hintz et al.(1982) showed that in GH deficient patients their IGF-II increased with acute and chronic GH treatment. They also suggested that IGF-II is partly GH dependent. However, our data differ from theirs. Zapf et al. have shown that the mean IGF-II values in acromegalic patients were the same as those in normal subjects, but in their data there were several patients with a higher concentration of IGF-II. Therefore, we suspect that some patients with acromegaly might have higher IGF-II than normal. The data for patients with anorexia nervosa suggest that the IGF-II concentration depends on nutritional conditions, but this dependency is also less than that of IGF-I. These results suggest that the IGF-II concentration in human plasma might be partially dependent on GH and/or nutritional conditions, and this dependency is less than that of IGF-I. The main control for plasma IGF-II needs to be clarified.
Our data concerning liver diseases, renal failure, and pregnant women are in accordance with those of other laboratories.
In patients with tumor associated hypoglycemia, plasma IGF-II increased slightly and IGF-I was low, and IGF-II in the tumor was high.
After tumor resection, IGF-I and II were back to normal. We suspect that hypoglycemia is due to IGF-II that was produced by the tumor. There have been several reports of similar cases in which the tumor secretes IGF-II and hypoglycemia occurs (Megyesi et al. 1974 , Hyodo et al. 1977 , Daughaday et al., 1981 , 1988 , Shapiro 1988 . In these cases, the immunoreactive plasma IGF-II concentration was normal or increased slightly and the tumor had increased concentration of IGF-II and IGF-II mRNA. Daughaday et al. (1980) reported that a tumor secreted high Vol.37, No.5 RIA FOR IGF-II molecular weight IGF-II and that a considerable loss of high molecular weight IGF-II may have occurred during the acidethanol extraction process, and a loss of IGF-II may have occurred in storage.
They also showed that in these cases IGF-II was higher in radioreceptor assay than in radioimmunoassay.
Therefore the reason why the immunoreactive plasma IGF-II concentration was not extremely high might be the loss of IGF-II and the molecular heterogeneity of IGF-II. It is interesting to study the molecular weight, receptor reactivity and bioactivity of IGF-II in our cases.
There would be many patients with tumor-associated hypoglycemia and we could determine the cause in some patients by means of the assay of IGFs.
With this sensitive and specific RIA of IGF-II with biosynthetic IGF-II we were able to measure IGF-II in human plasma and might measure small amounts of IGF-II in tissue or cerebrospinal fluid, which is usable in evaluating the role of IGF-II.
